uniQure Reports Q3 2025 Revenue Increase to $3.7 Million, Net Loss of $80.5 Million

uniQure N.V. reported its financial results for the third quarter of 2025, revealing a total revenue of $3.7 million, a significant increase from $2.3 million in the same period last year. The rise in revenue was primarily driven by a boost in license revenues, which reached $3.6 million compared to $2.1 million in the prior year. However, the company also reported a net loss of $80.5 million for the quarter, up from a loss of $44.4 million in Q3 2024. For the nine months ending September 30, 2025, total revenues were $10.5 million, down from $21.9 million in the same period last year, largely due to the absence of contract manufacturing revenues following the divestiture of its commercial manufacturing facility.

The company's operational expenses for the third quarter totaled $54.2 million, compared to $43.2 million in the previous year, reflecting increased spending in research and development (R&D) and selling, general, and administrative (SG&A) expenses. R&D expenses rose to $34.4 million from $30.6 million, while SG&A expenses increased to $19.4 million from $11.6 million. The increase in expenses was attributed to ongoing clinical trials and preparations for potential commercialization of its lead product candidate, AMT-130, for Huntington's disease.

uniQure has made strategic advancements, including a follow-on public offering in September 2025 that generated net proceeds of approximately $323.7 million. This funding is expected to support the ongoing development of its gene therapy pipeline, which includes AMT-130, AMT-260 for temporal lobe epilepsy, AMT-191 for Fabry disease, and AMT-162 for amyotrophic lateral sclerosis. The company also amended its loan facility with Hercules Capital, allowing for additional funding contingent on the approval of AMT-130.

As of September 30, 2025, uniQure reported cash and cash equivalents of $597.1 million, a substantial increase from $158.9 million at the end of 2024. The company anticipates that its current cash resources will be sufficient to fund operations into 2029, covering ongoing clinical trials and potential commercialization efforts. However, the company acknowledged the need for additional financing in the future, particularly if it requires further capital to support its product development and commercialization strategies.

Looking ahead, uniQure faces uncertainties regarding the regulatory approval process for AMT-130, particularly following recent discussions with the FDA that raised questions about the adequacy of data from its Phase I/II studies for a Biologics License Application (BLA) submission. The company remains committed to advancing its clinical programs and is focused on addressing the challenges associated with regulatory compliance and market acceptance of its gene therapies.